LVAD Will Improve Cardiac Output in Non-Ischemic Biventricular Cardiomyopathy with EF 8%
Yes, an LVAD will mechanically improve cardiac output in this patient, but the critical concern is whether biventricular support (BiVAD) or total artificial heart (TAH) is needed rather than LVAD alone, given the biventricular involvement and extremely low ejection fraction.
Primary Hemodynamic Consideration
An LVAD will directly augment cardiac output by mechanically unloading the left ventricle and providing forward flow. In continuous-flow LVADs, actuarial survival reaches 80% at 1 year and 70% at 2 years 1. The device provides hemodynamic support with cardiac index improvements from approximately 1.6 to 3.2 L/min/m² 2.
The Biventricular Failure Problem
The major challenge here is the biventricular involvement. With an EF of 8%, this patient likely has significant right ventricular dysfunction alongside left ventricular failure. The guidelines are explicit: evaluation of RV function is crucial since postoperative RV failure greatly increases perioperative mortality 1.
Key Decision Points for Device Selection:
- If RV failure is potentially reversible: Consider LVAD with temporary RVAD support (days to weeks) using a centrifugal pump 1
- If chronic biventricular failure or high risk for persistent RV failure: BiVAD implantation may be necessary 1
- Critical limitation: Patients requiring long-term BiVAD support must be transplant-eligible, as BiVAD therapy is not suitable for destination therapy 1
The hemodynamic definition of biventricular failure includes: cardiac index <2.0 L/min/m², right atrial pressure and pulmonary capillary wedge pressure >16 mmHg, CVP to PCWP ratio >0.63, and low RV stroke work index 3.
Non-Ischemic Etiology: A Potential Advantage
The non-ischemic etiology is actually favorable for this patient. Young patients with non-ischemic cardiomyopathy have higher likelihood of myocardial recovery during LVAD support 4. In patients with non-ischemic cardiomyopathy and <1 year history of heart failure, 13% achieved sufficient recovery for device explantation 4. Recovery is more likely in younger patients with acute fulminant but reversible causes such as acute myocarditis or peripartum cardiomyopathy 1.
Specific Hemodynamic Targets Post-LVAD
If LVAD (with or without temporary RVAD) is pursued, target these parameters 5:
- CVP: 10-15 mmHg (decreases wall tension, optimizes ventricular interdependence)
- Cardiac index: >2.0, ideally 2.4 L/min/m²
- MAP: >65 mmHg (improves RV supply/demand balance)
- Heart rate: 90-110 bpm (RV stroke volume may be maximal; cardiac output improves with faster HR)
- Early use of inhaled epoprostenol or nitric oxide to recouple RV to pulmonary artery
Critical Caveats
BiVAD outcomes are inferior to LVAD alone 1, so the indication should be discussed before RV function deteriorates further
For non-ischemic cardiomyopathy with small LV cavities (restrictive physiology), continuous axial flow LVAD therapy is feasible but associated with more right heart failure, prolonged inotropic support, and infections 6
Restrictive and infiltrative cardiomyopathies (e.g., amyloid) may be uniquely suited to TAH rather than BiVAD 3
Device-related complications remain significant: bleeding, thromboembolism, stroke, pump thrombosis, driveline infections, and device failure 1
Recommendation Algorithm
- Immediate assessment: Comprehensive RV function evaluation via echocardiography and right heart catheterization
- If RV dysfunction appears reversible: Proceed with LVAD + plan for temporary RVAD if needed
- If chronic severe biventricular failure: Consider BiVAD (only if transplant-eligible) or TAH
- If restrictive/infiltrative cardiomyopathy: Consider TAH over BiVAD
- Ensure transplant candidacy if BiVAD is being considered, as it cannot serve as destination therapy
The LVAD will improve cardiac output, but careful preoperative RV assessment and device selection (LVAD vs. BiVAD vs. TAH) are essential to optimize survival in this critically ill patient with biventricular involvement.